Coppersmith Presentation to Alere Inc Stockholders

PAGE 43 | COPPERSMITH "So we're In the process of adding 200 salespeople, with all the head count going towards primarily in Asia, but also in Europe, but some in the States, but primarily in Asia and Europe; and all the focus being on the new products." - Chairman and CEO Ron Zwanziger at the J.P. Morgan Global Healthcare Conference 1/12/11 SG&A: Overspending In Anticipation of Growth That Has Not Come ■ Starting in 2010, Alere increased global sales force by 20% for expected new product sales that have hugely disappointed Alere has exhibited a general tendency to build inappropriate scale for an organization of its size and scope "As I said, I think our SG&A Is too high particularly in the cardiology and the Infectious disease side. The reason for that is because we spent the last several years building our system around the world, which we now have formed. We're In 35 markets around the world directly, with full sales and marketing and capabilities and in many cases - in many of those countries, not all our product are on sale..." - Chairman and CEO Ron Zwanziger at the J.P. Morgan Global Healthcare Conference 1/9/13 > Alere has built a worldwide empire that it touts as a strategic strength, even as it impinges profitability and Alere lacks the product breadth to utilize it Alere suffers continued negative leverage on the SG&A line despite billions of dollars spent on acquisitions

View entire presentation